Bio-Rad launches four anti-idiotypic antibodies and a new anti-MMAE antibody range, enhancing bioanalytical assay development for preclinical research and clinical trials.
ddSEQ™ Single-Cell 3' RNA-Seq Kit and Omnition v1.1 Analysis Software Enable High-Quality and Affordable Single-Cell Transcription and Gene Expression to Support Molecular Biology, Oncology, and Drug Discovery Research
Bio-Rad's Range of StarBright Dyes Conjugated to Highly Validated Antibodies Now Totals 32 Dyes, Providing Greater Choice and Flexibility for Conventional and Full-Spectrum Flow Cytometry in Immunology Research.
Collaboration Aims to Provide Researchers Cutting-Edge Tools to Enable Transformational Monitoring of Key Biomarkers in Solid Tissue Transplants.
Collaboration Aims to Grow Clinical Evidence Supporting the use of Bio-Rad’s ddPCR™ Technology for Molecular Residual Disease Monitoring of Patients across a Range of Solid Tumor Types
Highly Sensitive and Multiplexed Assay for the Detection, Discrimination, and Quantification of Key Mutations in ESR1 Gene for Breast Cancer, Developed for Bio-Rad’s QX600™ Droplet Digital™ PCR System
Antibodies Validated for Use with Bio-Rad’s Celselect Slides™ Enumeration Stain Kits Enable Immunolstaining of Captured Circulating Tumor Cells in Liquid Biopsy Samples
The dd-Check STEC Solution is the First Droplet Digital™ PCR Method Approved by AOAC
Rapid, Sensitive, and Validated Detection of Viral Replication Genes Using Droplet DigitalTM PCR During Cell and Gene Therapy Production
Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and drug monitoring.